AR and neoplasm: In a longitudinal study by Boers et al. in postmenopausal patients with AR-positive metastatic breast cancer receiving bicalutamide therapy, [18F]FDHT was able to track reductions in tumor uptake 4–6 weeks following treatment, but these reductions did not correlate consistently with therapy responses.